Cargando…

Effect of roxadustat on iron metabolism in patients with peritoneal dialysis: a real-world 24-week study

BACKGROUND: Roxadustat is an oral hypoxia inducing factor-prolyl hydroxylase inhibitor (HIF-PHI) that regulates iron metabolism in patients with chronic kidney disease (CKD) primarily by reducing hepcidin levels and mobilizing internal iron stores. More data are needed to demonstrate the efficacy of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Xuejie, Jia, Ruoyu, Zheng, Zhifang, Jiang, Luhua, Xu, Yizhou, Raj, Ashok, Sun, Dong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10629011/ https://www.ncbi.nlm.nih.gov/pubmed/37936193 http://dx.doi.org/10.1186/s40001-023-01465-0

Ejemplares similares

Effects of Roxadustat on the Anemia and Iron Metabolism of Patients Undergoing Peritoneal Dialysis
por: Hirai, Keiji, et al.
Publicado: (2021)

Short-term effects of roxadustat on serum copper and iron changes in a peritoneal dialysis patient
por: Nakamura, Hironori, et al.
Publicado: (2022)

Efficacy of roxadustat in treatment of peritoneal dialysis patients with renal anaemia
por: Zhu, Xin-Wang, et al.
Publicado: (2021)

Evaluating the effect of Roxadustat on ventricular repolarization in patients undergoing peritoneal dialysis
por: Zhang, Yangyang, et al.
Publicado: (2023)

Efficacy of Roxadustat on anemia and residual renal function in patients new to peritoneal dialysis
por: Wu, Tong, et al.
Publicado: (2022)

Comparison of risk of peritoneal dialysis-associated peritonitis between roxadustat and recombinant human erythropoietin in peritoneal dialysis patients: a retrospective comparative cohort study
por: Zhang, Wei, et al.
Publicado: (2022)

Effects of roxadustat on anemia, iron metabolism, and lipid metabolism in patients with non-dialysis chronic kidney disease
por: Hirai, Keiji, et al.
Publicado: (2023)

Randomized Study on the Efficacy of Standard Versus Low Roxadustat Dose for Anemia in Patients on Peritoneal Dialysis
por: Yang, Zhikai, et al.
Publicado: (2021)

Roxadustat for CKD-related Anemia in Non-dialysis Patients
por: Coyne, Daniel W., et al.
Publicado: (2020)

Pooled Analysis of Roxadustat for Anemia in Patients With Kidney Failure Incident to Dialysis
por: Provenzano, Robert, et al.
Publicado: (2020)

Comparison between the influence of roxadustat and recombinant human erythropoietin treatment on blood pressure and cardio-cerebrovascular complications in patients undergoing peritoneal dialysis
por: Cheng, Shuiqin, et al.
Publicado: (2023)

Phase 3 Study of Roxadustat to Treat Anemia in Non–Dialysis-Dependant CKD
por: Akizawa, Tadao, et al.
Publicado: (2021)

Changes of biomarkers for erythropoiesis, iron metabolism, and FGF23 by supplementation with roxadustat in patients on hemodialysis
por: Yoshida, Shunsuke, et al.
Publicado: (2023)

Population pharmacokinetics of roxadustat in Japanese dialysis‐dependent chronic kidney disease patients with anaemia
por: Takada, Akitsugu, et al.
Publicado: (2021)

Iron Parameters in Patients Treated with Roxadustat for Anemia of Chronic Kidney Disease
por: Ganz, Tomas, et al.
Publicado: (2023)

24 Improved Dialysis Symptom Index with Tablo Thrice Weekly Dialysis
Publicado: (2021)

Intermittent Oral Dosing of Roxadustat in Peritoneal Dialysis Chronic Kidney Disease Patients with Anemia: A Randomized, Phase 3, Multicenter, Open‐Label Study
por: Akizawa, Tadao, et al.
Publicado: (2019)

Effect of roxadustat on intact and C-terminal FGF23 levels in patients undergoing peritoneal dialysis: a post hoc analysis of a randomized trial
por: Wang, Zi, et al.
Publicado: (2023)

Roxadustat: Not just for anemia
por: Zhu, Xiaoyu, et al.
Publicado: (2022)

Comparison of peritoneal transport characteristics at the second week and at six months of peritoneal dialysis commencement
por: Balasubramaniyam, R., et al.
Publicado: (2013)

Clinical Pharmacokinetics and Pharmacodynamics of Roxadustat
por: Czock, David, et al.
Publicado: (2021)

Combination of once-weekly haemodialysis with peritoneal dialysis is associated with lower mortality compared with peritoneal dialysis alone: a longitudinal study
por: Murashima, Miho, et al.
Publicado: (2020)

Comparison of sodium removal in peritoneal dialysis patients treated by continuous ambulatory and automated peritoneal dialysis
por: Maharjan, Sarju Raj Singh, et al.
Publicado: (2019)

Safety and Effectiveness of Roxadustat in Dialysis-Dependent Patients With Renal Anemia: A Hospital-Based Cohort Study
por: Moussa, Oumarou, et al.
Publicado: (2022)

Roxadustat in treating anemia in dialysis patients (ROAD): protocol and rationale of a multicenter prospective observational cohort study
por: Zhang, Yaling, et al.
Publicado: (2021)

Effect of Kidney Function and Dialysis on the Pharmacokinetics and Pharmacodynamics of Roxadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor
por: Groenendaal-van de Meent, Dorien, et al.
Publicado: (2020)

The impact of peritoneal dialysis-related peritonitis on mortality in peritoneal dialysis patients
por: Ye, Hongjian, et al.
Publicado: (2017)

Roxadustat and thyroid-stimulating hormone suppression
por: Tokuyama, Atsuyuki, et al.
Publicado: (2021)

Efficacy and Mechanism of Roxadustat plus Oral Iron in the Treatment of Elderly Chronic Kidney Disease with Anemia
por: Liu, Bo, et al.
Publicado: (2022)

Hypoxia-inducible factor upregulation by roxadustat attenuates drug reward by altering brain iron homoeostasis
por: Yan, Pengju, et al.
Publicado: (2023)

Taurolidine Peritoneal Dialysis Catheter Lock to Treat Relapsing Peritoneal Dialysis Peritonitis
por: Alvarez Nadal, Marta, et al.
Publicado: (2020)

Peritoneal Dialysis
por: Pyper, R. A.
Publicado: (1948)

Peritoneal Dialysis
por: Taskapan, Hulya, et al.
Publicado: (2011)

Fatigue in incident peritoneal dialysis and mortality: A real-world side-by-side study in Brazil and the United States
por: Guedes, Murilo, et al.
Publicado: (2022)

Efficacy and Cardiovascular Safety of Roxadustat in Dialysis-Dependent Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies
por: Barratt, Jonathan, et al.
Publicado: (2021)

Response to roxadustat in a patient undergoing long-term dialysis and allergic to erythropoiesis-stimulating agents: A case report
por: Xu, Cai, et al.
Publicado: (2022)

The efficacy and safety of roxadustat for anemia in patients with dialysis-dependent chronic kidney disease: a systematic review and meta-analysis
por: Zhou, Qiaoqiao, et al.
Publicado: (2023)

Retracted: Efficacy and Mechanism of Roxadustat plus Oral Iron in the Treatment of Elderly Chronic Kidney Disease with Anemia
por: and Alternative Medicine, Evidence-Based Complementary
Publicado: (2023)

Effects of Roxadustat on Erythropoietin Production in the Rat Body
por: Yasuoka, Yukiko, et al.
Publicado: (2022)

Roxadustat: Do we know all the answers?
por: Li, Qiu-Yu, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_b927h5629sj82h55ag1chrupto